Nano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer Patients

IMUNON Inc IMNN stock is surging on Tuesday, with a strong session volume of 117.8 million as per data from Benzinga Pro.

The nano-cap company released topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced ovarian cancer.

OVATION 2 is a randomized study of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy (NACT) inclusive of interval debulking or cytoreductive surgery compared with a control arm of standard-of-care NACT alone.

IMNN-001 is the company’s interleukin-12 (IL-12) immunotherapy based on its TheraPlas technology.

Highlights from patients treated with IMNN-001 plus standard-of-care in a first-line treatment setting include:

• An 11.1-month increase in median overall survival compared with standard-of-care alone in the intent-to-treat population (ITT).
• A hazard ratio in the ITT population of 0.74 indicates a 35% improvement in survival.
• Among the approximately 90% of trial participants who received at least 20% of specified treatments per protocol in both study arms, patients in the IMNN-001 arm had a 15.7-month increase in median OS, representing a further extension of life with a hazard ratio of 0.64, a 56% improvement in survival.
• For the nearly 40% of trial participants treated with a poly ADP-ribose polymerase (PARP) inhibitor, the hazard ratio decreased further to 0.41, with median overall survival in the IMNN-001 treatment arm not yet reached at the time of database lock, compared with the median overall survival of 37.1 months in the standard-of-care treatment arm.

The PFS results, the trial’s primary endpoint, support the OS results with:

• A three-month improvement in PFS compared with standard-of-care alone.
• A hazard ratio in the intent-to-treat population of 0.79, indicating a 27% improvement in delaying progression for the IMNN-001 treatment arm.

IMUNON plans to hold an End-of-Phase 2 meeting with the FDA as soon as possible to discuss the protocol for a Phase 3 study, which is anticipated to begin in the first quarter of 2025.

Price Action: IMNN stock is up 158% at $3.07 at last check Tuesday.

Read Next:

• Merck’s Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast.

Don’t miss the opportunity to dominate in a volatile market at the Benzinga SmallCAP Conference on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you’re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!

Image by PDPics from Pixabay